Human growth hormone lawsuits
Bio-Technology General asks New Jersey state court March 29 to affirm its position that a non-compete agreement with Serono expires in the middle of the year. Serono maintains that a co-promotion agreement between the two companies for its Saizen hGH brand was improperly terminated and that the non-compete agreement should remain in effect. BTG hopes to launch its own hGH brand July 1; Teva will promote the product. In January, a federal court ruled in favor of BTG in patent litigation against Genentech. Genentech is appealing
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth